Skip to main content

Cardio Intelligence

Category: AI in Healthcare

AI-powered medical device software for continuous heart monitoring and ECG analysis, focusing on detecting cardiac arrhythmias, particularly atrial fibrillation Cardio Intelligence was founded in 2019. The company is led by Yuichi Tamura (Representative Director) & Shigemasa Sasaki (Director CEO). Based in Tokyo, Japan. Team size: 20. Total funding raised: $6.69M. Latest round: Series B. Key investors include Shin Nippon Biomedical Laboratories, Tokai Tokyo Investment, Iwagin Business Creation Capital, Orthomos Investment, Samurai Incubate, Nissay Capital, ANRI, SMBC Venture Capital, Daiwa Corporate Investment, M3, Gemseki, Shizuoka Capital.

Founded
2019
Headquarters
Tokyo, Japan
Team size
20
Total funding
$6.69M

Value proposition

Provides accurate, real-time cardiac diagnostics through AI-driven ECG analysis, enabling early detection of arrhythmias with explainable AI technology, reducing analysis time from hours to minutes

Products and solutions

SmartRobin AI Series (core ECG analysis platform), SmartPAFin Series (paroxysmal atrial fibrillation征兆 detection software, approved Dec 2024), Long-term ECG analysis software, Cloud-based data analytics platform for healthcare providers, AI-powered diagnostic imaging solutions

Unique value

Proprietary explainable AI algorithms trained on over 100 million heartbeats, combined with continuous monitoring capabilities for real-time cardiac analysis, focusing on paroxysmal atrial fibrillation detection

Target customer

Healthcare providers, cardiology clinics, hospitals, and medical institutions requiring continuous cardiac monitoring and ECG analysis

Industries served

Cardiology, Medical Device Manufacturing, Digital Health, Hospital Diagnostics, Remote Patient Monitoring, Healthcare Technology

Technology advantage

Advanced deep learning models that achieve high diagnostic accuracy comparable to expert cardiologists while reducing analysis time from 8 hours to 3 minutes for 24-hour ECGs, with medical device certification in Japan

How they differentiate

Cardio Intelligence differentiates through its explainable AI technology, medical device certification in Japan, focus on paroxysmal atrial fibrillation detection, and ultra-fast processing capabilities while maintaining specialist-level accuracy

Main competitors

PMcardio (Powerful Medical), Cardiologs (Philips), Cardio.AI, AliveCor, iRhythm Technologies

Key partnerships

JSR Corporation (joint development), International University of Health and Welfare (industry-academia collaboration), GE Healthcare (integration platforms), UltraLinQ (diagnostic imaging), Shin Nippon Biomedical Laboratories (joint R&D on AI ECG analysis, 2025), Tottori University Hospital (clinical research on SmartPAFin, 2025)

Notable customers

150+ medical institutions in Japan, National Hospital Organization, Tokyo Metropolitan Government hospitals

Major milestones

Secured Series B first close for overseas expansion (2025), Received medical device certification in Japan (2021), Developed SmartRobin AI technology for continuous ECG analysis, ISO 27001 certification obtained (2023), Patent No. 7002168 obtained, 150+ medical institutions adopted the technology, SmartPAFin Series received regulatory approval in Japan (2024-12), Series B second close with Orthomos Investment and new dual CEO structure (2026-03)

Growth metrics

150+ medical institutions using SmartRobin AI Series as of November 2025, processing ECGs 60x faster than manual analysis; SmartPAFin received regulatory approval Dec 2024

Market positioning

Positioned as a specialist in continuous cardiac monitoring with a focus on high-accuracy AI-driven ECG analysis for arrhythmia detection, particularly in the Japanese market with expansion to Asia and North America

Geographic focus

Primarily focused on Japan with 150+ medical institutions using SmartRobin AI, with expansion plans to Asia and North America following Series B funding

Patents and IP

Patent No. 7002168 obtained in Japan, additional patents pending for AI ECG analysis workflows

About Yuichi Tamura (Representative Director) & Shigemasa Sasaki (Director CEO)

Yuichi Tamura: Medical doctor (MD, PhD), cardiologist, professor at International University of Health and Welfare, founder of Cardio Intelligence. Shigemasa Sasaki: Serial entrepreneur with 25+ years in biopharma, diagnostics, medical devices; global M&A and startup management experience.

Official website: